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Abstract
The rising use of titanium dental implants has increased the prevalence of peri-implant disease that 
shortens their useful life. A growing view of peri-implant disease suggests that plaque 
accumulation and microbiome dysbiogenesis trigger a host immune inflammatory response that 
destroys soft and hard tissues supporting the implant. The incidence of peri-implant disease is 
difficult to estimate, but with over 3 million implants placed in the USA alone, and the market 
growing by 500,000 implants/year, such extensive use demands additional interceptive approaches. 
We report a water-based, nonsur-gical approach to address peri-implant disease using a 
bifunctional peptide film, which can be applied during initial implant placement and later 
reapplied to existing implants to reduce bacterial growth. Bifunctional peptides are based upon a 
titanium binding peptide (TiBP) optimally linked by a spacer peptide to an antimicrobial peptide 
(AMP). We show herein that dental implant surfaces covered with a bifunctional peptide film kill 
bacteria. Further, using a simple protocol for cleaning implant surfaces fouled by bacteria, the 
surface can be effectively recoated with TiBP-AMP to regain an antimicrobial state. Fouling, 
cleansing, and rebinding was confirmed for up to four cycles with minimal loss of binding 
efficacy. After fouling, rebinding with a water-based peptide film extends control over the oral 
microbiome composition, providing a novel nonsurgical treatment for dental implants.
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There is a continuing need to improve patient treatment based on the therapeutic advantages 
offered by titanium dental implants. However, a complex biofilm rapidly forms on the 
surface of any dental implant once placed in the oral cavity. Within several weeks, the 
biofilm consists of typical subgingival bacterial species, including keystone periodontal 
pathogens such as Porphyromonas gin-givalis, Aggregatibacter actinomycetemcomitans, 
Tannerella forsythia, Treponema denticola, and Prevotella intermedia.1 The relative 
abundance of commensal bacterial species to periodontal pathogens shifts with dysbiosis 
and too often induces the host to mount an inflammatory response leading to peri-implant 
diseases. This starts with peri-implant mucositis and can culminate with peri-implantitis, 
resulting in loss of soft and hard tissue anchoring the implant in the jaw, thus threatening 
and/or reducing the implant’s useful life.
The expanded use of implants in dental treatment coupled with the rising prevalence of peri-
implant disease threatens to shorten implant life and lead to implant failure in increasing 
numbers of patients.2,3 Recent consensus on peri-implant disease points to plaque 
accumulation and microbial dysbiogenesis as the major factors triggering the host immune 
inflammatory response.4–6 Millions of implants are placed yearly around the world, with 3 
million placed in the USA alone and rising at 500,000/annum.7 Reduced service life and 
eventual implant failure will therefore have a growing adverse impact on public health, with 
an increase in healthcare cost. On the other hand, effective treatment for peri-implant disease 
would make the benefits of implants available to a wider group of high-risk patients.8,9
Despite a high success rate, within 5 years of placement, a small percentage (4–8%) of 
implants fail,10–12 and a higher percentage fail in patients with chronic illness, advanced 
age, and/or poor periodontal health.9,13–15 A Cochrane metaanalysis report estimated the 
incidence of peri-implantitis as 1.6% after 3 years and 5.5% at 10 years.16,17 In contrast, 
Derks and colleagues placed the incidence of peri- implantitis at ~ 14.5% after 9 years of 
service,18 while others identified clinically significant, nonlinear bone loss as early as after 3 
years of function in more than ~ 80% of patients.18 With implant use growing, increasing 
implant loss has a profound financial healthcare cost, with the potential for loss of public 
confidence in the dental profession.
There is currently no definitive means for controlling or eliminating the bacterial biofilm on 
implants.19–21 Current state-of-the-art treatments for implants are similar to those for 
periodontal disease and include mechanical debridement and/or medicinal means intended to 
retard the biofilm. For implant surfaces, these include abrasive cup polishing, abrasive air 
blasting, titanium brushes with cleansing agents such as sodium hypochlorite or povidone-
iodine, chlorohexidine rinses, antibiotics, and antimicrobials. Each treatment can be used 
alone or in concert by dental professionals. Successful treatment for peri-implant disease 
must also recognize the need to maintain biocompatibility, osteogenic competency, and cell 
viability at the implant surface to obtain favorable host cell responses.20–22 Thus, a 
commonly held goal remains to control the oral microbiota in order to arrest or slow hard 
and soft tissue destruction by the host inflammatory response.
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There have been numerous attempts to boost implant surface performance using biologically 
active signals.23–30 However, the majority of these have required passive absorption or 
chemical coupling to the surface.31–33 Absorption leads to leaching and poor performance. 
Covalent coupling has also met with limited success, because coupling agents (e.g., thiols, 
carboxylic acids, hydroxyl, guanidines, and amines) creates hostile environments to 
bioactive molecules, leading to loss of bioactivity31,34 and/or incorrect display of the 
bioactivity to the cellular environment. Moreover, these hostile coupling environments can 
be used only during manufacturing and not at recall appointments, long after placement, 
when the longevity of the implant is threatened. Ideally, both strong affinity to the implant 
surface and maintenance of the antimicrobial state are required.
Peri-implantitis has become a growing concern in the oral health community due to the 
increasing popularity of dental implants to restore form and function. Because, at present, 
none of the nonsur-gical treatments result in a superior outcome, there is a lack of consensus 
with respect to predictable treatments for peri-implantitis, making treatment choices all but 
unmanageable for clinicians and patients. With the number of dental implants continuing to 
rise, there is an urgent need to identify a strategy that can further slow or even prevent peri-
implantitis. Successful approaches will require novel and rational engineering design that 
can leverage the multifaceted characteristics of biomolecules, as well as providing structural 
and functional properties at the material-tissue interface.35,36
Using a combination of experimental and computational bioengineering approaches, we 
engineered a bifunctional peptide to provide a biocompatible, water-based, easy-to-apply, 
durable peptide film that exhibits antimicrobial activity. The bifunctional peptide can be 
repeatedly applied at recall appointments for continued treatment of peri-im-plantitis to 
extend implant longevity. Reapplication offers a safe, inexpensive, water-based bifunctional 
peptide film to treat existing implants at recall appointments, to arrest disease progression as 
a viable peri-implantitis treatment strategy compared with current state-of-the-art treatments.
EXPERIMENTAL PROCEDURES
Synthesis and Purification of Bifunctional Peptides
Peptides were produced with an AAPPTec Focus XC automated solid-phase peptide 
synthesizer using standard fluorenylmethyloxycarbonyl (Fmoc) chemistries and Wang 
resins.23 To remove the Fmoc protecting group, Wang resins preloaded with the first amino 
acid protected by a Fmoc group were treated with 20% piperidine in dimethylformamide 
(DMF). Fmoc deprotection was monitored by ultraviolet (UV) absorbance, and the 
deprotected resin was then washed with DMF to remove piperidine. Modified amino acids 
with protected side chains and Fmoc were solubilized in DMF at concentration of 0.2 M and 
added in sevenfold excess. In a separate measuring vessel, amino acids in solution were 
activated with 0.4 M O-benzotriazole-N,N,N’,N’-te-tramethyluronium hexafluorophosphate 
(HBTU) in DMF and 1 M 4-methylmorpholine (NMM). The activated amino acid was then 
added to the reaction vessel and mechanically mixed under nitrogen gas for 45 min to couple 
the amino acid to the resin. Double coupling was used for each amino acid in the sequences. 
After amino acid addition, the resin was washed with DMF and the protocol applied again 
for each subsequent amino acid.
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Following synthesis, the resins with synthesized peptides were dried with reagent-grade 
ethanol to remove residual DMF. The peptides were cleaved from the resin, and the side-
chains were deprotected using Reagent K [trifluoroacetic acid (TFA)/ thioanisole/H2O/
phenol/ethanedithiol (87.5:5:5:2.5)] and precipitated using cold ether. Crude peptides were 
purified using reversed-phase (RP) high-performance liquid chromatography (HPLC), then 
lyophilized and stored at – 20°C.
Minimum Inhibitory Concentration (MIC)
The MIC of TiBP-AMP was determined spectropho- tometrically against Streptococcus 
mutans bacteria. Bacteria were cultivated and grown to mid-log phase. Serial dilutions, 
beginning at 256 μM peptide concentration, were added to wells containing a final bacterial 
concentration of 1 × 107 colony-forming units (CFU)/mL in a 96-well plate and grown at 
37°C for 24 h. Absorbance at 600 nm was monitored using a Cytation 3 microplate reader. 
Control samples consisted of 1 × 107 CFU/mL bacteria only.
Titanium Implant Disc Preparation
Coin-shaped titanium implant discs, 10 mm in diameter and 0.5 mm thick, made from grade 
4 titanium (USC Engineering Shop) were lap polished and grit blasted with 180–220 micron 
titanium dioxide particles and cleaned following a published protocol.37 Briefly, the cleaning 
protocol was to sonicate the discs in water, 70% ethanol, 40% sodium hydroxide, and 50% 
nitric acid, followed by rinsing with water and autoclaving prior to use.
Bacterial Culture and Maintenance
Streptococcus mutans ATCC 700610 was cultured according to the ATCC protocol in brain 
heart infusion (BHI) broth (BD Difco).38 Several drops of rehydrated frozen stock of 
bacteria were streaked on a BHI agar plate and incubated for 24 h at 37°C and 5% CO2. A 
single colony was removed from the agar plate and used to inoculate 5 mL of appropriate 
medium followed by incubation overnight. Bacteria were grown to mid-log phase with final 
concentration of 107 CFU/mL.
Bifunctional Peptide Binding on Titanium Discs
New, sterile titanium discs were functionalized with bifunctional peptides by incubation with 
peptide solution at 37°C, specifically 100 μL of 100 μM concentration of bifunctional 
peptide for TiBP-AMP and C-AMP. Following incubation, the discs were washed in a 24-
well plate by pipetting 400 μL deionized (DI) water onto the wall of a well containing the 
disc and then removing the H2O. Each disc was washed three times. The same procedure 
was repeated for the rebinding step for disc fouled/cleaned of bacteria.
Fluorescence Imaging for Peptide Binding
Peptide binding was evaluated by pipetting 20 μL Pierce fluorometric peptide labeling 
reagent directly onto the previously peptide film-coated disc surface and incubating at room 
temperature, protected from light for 5 min. The discs were washed by holding the disc with 
forceps and pipetting water at a 45° angle, allowing the water to flow across the disc face. 
The discs were transferred to glass microscope slides, inverted, and imaged using an inverted 
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fluorescence microscope (Zeiss AxioPlus). The fluorescence images were saved both as a 
two-dimensional (2D) representation, and a three-dimensional (3D) representation in which 
the z-axis height corresponds to the fluorescence intensity. Peptide binding was quantified as 
the percentage surface coverage using ImageJ software version 1.52a.
Peptide Film Antibacterial Function on Titanium Discs
Peptide-functionalized discs were evaluated for antibacterial efficacy against S. mutans 
using the BacLight Live/Dead assay kit to differentiate living from dead bacteria present on 
the disc surface with selected bifunctional peptides compared with a water control. S. 
mutans (ATCC 700610) bacteria were grown and cultivated according to ATCC protocols. S. 
mutans bacteria (400 μL of 1 × 107 CFU/mL) were incubated with functionalized discs for 4 
h, then washed with 0.85% NaCl, according to manufacture recommendations, to remove 
any phosphates that could interfere with the Live/Dead stains. A solution of 30% stain [1:1 
ratio of propidium iodide (PI) to SYTO9] in 70% 0.85% NaCl solution was used to stain 
bacteria on the disc surface. The discs were then transferred to a glass microscope slide and 
inverted for fluorescence microscopy. Images of five unique locations on the discs were 
collected at 10 × magnification.
Implant Disc Cleaning for Rebinding
Discs were cleaned to remove bacteria, peptide, and salts using a method that is common to 
implant retreatment visits. An electric toothbrush with a round head slightly larger than the 
diameter of the disc was secured in a laboratory stand. A Petri dish filled with peri-plast wax 
was used as a base for insertion of 30-gauge needles in a triangular configuration 
surrounding the disc to prevent motion of the disc when the electric toothbrush was applied 
with 100 g force at 10 cm from the secured pivot point. A 1:10 solution of sodium 
hypochlorite was pipetted into the Petri dish, and the disc was brushed for 2 min, then 
removed and washed thoroughly with water. The disc was then air-dried in a sterile laminar 
flow hood in preparation for peptide rebinding. The rebinding protocol was identical to the 
initial binding protocol.
Retreatment Cycle Binding and Reapplication
A solution of 33 iM TiBP-AuBP in phosphate buffered saline was pipetted onto a titanium 
disc and incubated at room temperature for 1 h. Discs were washed once with DI H2O, then 
dried at room temperature. A solution of 50-nm gold nanoparticles (AuNPs; Ted Pella Inc, 
USA) was incubated at room temperature on the peptide-functionalized disc for 20 min. The 
discs were washed once with DI H2O and dried at room temperature. Next, a solution of 8 
μM green fluorescent protein-gold binding peptide fusion (GFPuv-AuBP) was incubated on 
the surface for 20 min, washed, dried, and imaged using a fluorescence microscope (Zeiss 
AxioPlus). The same procedure was applied for four repetitions of fouling/cleansing. All 
images were analyzed using ImageJ software (version 1.52a).
Surface Profilometry
Three-dimensional surface measurements of the discs were visualized using a white-light 
profilometer (Veeco Wyko NT 1100 optical profiler). Pictures were taken at 5 ×, 10 ×, and 
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50 × magnification. Nonoverlapping pictures were taken of the disc. To obtain images from 
the same disc coordinates, a grid was etched onto a glass slide that repeatedly oriented the 
disc in the same orientation and position. The profilometer was then manipulated to ensure 
that the same region of the disc was imaged for consistency and reproducibility.
De Novo Peptide Structure Prediction and 3D Model Generation from Amino Acid 
Sequence
The de novo 3D structural modeling approach available through the online service PEP-
FOLD 3.5 was implemented to generate Protein Data Bank (PDB) models for the five best 
models of each bifunctional peptide amino acid sequence.4 PEP- FOLD 3.5 generates 3D 
structural conformations of linear peptides of between 5 and 50 amino acids and provides 
PDB models for the five best structures. PEP-FOLD 3.5 generates peptide structures by 
assigning one of 27 structural alphabet (SA) terms to fragments of four amino acids 
overlapping by three. The SA generalizes the secondary structure by assigning geometric 
descriptors emitted by the hidden Markov model described by Maupetit et al.5 Three-
dimensional models are then generated from the fragments using a course-grained 
representation and refined by 30,000 Monte Carlo steps. The chimeric peptide sequences 
were input into the PEP-FOLD 3.5 online service, and 200 simulations were run assuming 
aqueous conditions and neutral pH. Once generated, the models were clustered and sorted 
using the Optimized Potential for Efficient Structure Prediction (sOPEP).7 Nonbiased 
modeling was applied.
3D Model Visualization and Recoloring
PDB files containing the secondary structure models generated by PEP-FOLD 3.5 were 
visualized and further analyzed using UCSF Chimera.8 The structures were colored 
according to the peptide domains composing the bifunctional peptides. The first functional 
domain was colored blue, the spacer was colored black, and the second functional domain 
was colored red. The structures were oriented so that the first functional domain was located 
at the bottom. The surface was added to the ribbon structure, and transparency of 80% was 
applied.
RESULTS
Antibacterial Activity in Solution
The bacterial growth curves of S. mutans bacteria grown in presence of serial dilutions of 
TiBP-AMP are shown in Fig. 1. The minimum concentration of TiBP-AMP required to 
inhibit S. mutans bacterial growth was found to be 64 μM. The lowest concentration 
evaluated, viz. 8 μM, showed no bacterial inhibition, while in contrast, 256 μM resulted in 
no growth of S. mutans.
Implant Disc Preparation and Cleansing
Discs were cleaned using a method common to periodontal therapy39,40 that does not 
adversely affect clinical attachment. Hypochlorous acid (NaOCl) and a rotary electric 
toothbrush (Supplementary Fig. S1) were used as a clinically relevant cleaning method to 
allow rebinding of bifunctional peptide film to the implant surface.
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Binding and Rebinding of the Bifunctional Peptide
The top panels of Fig. 2 depict TiBP-AMP and Control-AMP (AMP without the TiBP 
domain) binding on titanium discs. Binding was quantified as percentage surface coverage 
and determined to be 46.8% for TiBP-AMP and 0.2% for Control-AMP (Table I). Rebinding 
following bacterial fouling and a clinically relevant cleaning procedure is shown in the 
middle panels of Fig. 2. The cleaned disc was recoated with the same peptides, and the 
surface coverage for TiBP-AMP was determined to be 28.5% (Table I) compared with 0.2% 
for Control-AMP (Table I). After bacterial fouling, cleaned discs retained 60% of the 
original binding capacity. The absence of binding of the control bifunctional peptide to the 
cleaned discs demonstrates scant amounts of nonspecific adherence of the peptide to 
bacterial debris.
Antibacterial Functionalization on Implant Discs
Discs were purposely inoculated with S. mutans to represent implant fouling to evaluate 
peptide film surface coverage on dental implant surfaces. The lower panels of Fig. 2 show 
the difference in the antibacterial properties between discs treated with TiBP-AMP versus 
Control-AMP. The percentage surface coverage of dead bacteria on the TiBP-AMP disc was 
19.3%, compared with 0.2% for the control (Table II). There was a significant difference of 
53.3% living bacteria on the control disc compared with 1.7% on the TiBP-AMP disc (Table 
II).
Retreatment Cycle Binding and Reapplication
Figure 3 shows the binding on titanium discs fouled up to four times. The bifunctional 
peptide TiBP-AuBP was revealed by incubation with gold nanoparticles that bind to AuBP 
(gold binding peptide). A fusion protein with green fluorescent protein (GFPuv-AuBP) was 
used to identify peptides via the GFP fluorescence signal that were bound to the AuNPs on 
TiBP-AuBP film attached to the titanium disc surface in a “sandwich” technique. Minimal to 
no fluorescence was observed for bare titanium discs and for discs function-alized with 
TiBP-AuBP + AuNP, and no signal for discs functionalized with GFPuv-AuBP fusion 
protein only. The fluorescence of the discs was measured using ImageJ, and the results for 
TiBP-AuBP + AuNP + GFPuv-AuBP are depicted as percentage surface coverage in Table 
III.
De Novo Secondary Structure Generation
Secondary structures were generated for the three bifunctional peptides studied herein. The 
secondary structures for TiBP-AMP, Control-AMP, and TiBP-AuBP are depicted in Fig. 4. 
The domains were recolored, so that blue indicates the first functional domain (TiBP or 
Control), black indicates the spacer, and red indicates the second functional domain (AMP 
or AuBP).
Titanium Disc Surface Topography
Surface topography characterization is summarized in Fig. 5. The average, root-mean-square 
(RMS), and range of the roughness are reported for bacteria-fouled titanium discs after 
cleaning and for the TiBP-AMP after rebinding to the titanium discs. There was no 
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significant change in the surface topography characteristics among the samples. The 
standard deviation for the sterile discs is due to it being lap polished and then blasted with 
80 mesh titanium oxide to reproduce the roughened surface which improves 
osteointegration. The “sterile disc” was never coated by functional film and therefore 
represents the air-jet-blasted rough surface.
DISCUSSION
Antibacterial Activity in Solution
The antibacterial activity of TiBP-AMP was established. Critical to the success of the 
bifunctional peptide on the surface is the antimicrobial function of the AMP domain when 
joined to the anchoring domain created by a titanium binding peptide (TiBP) through an 
engineered spacer (Fig. 4). The titanium binding peptide has been previously reported to 
effectively serve as a self-assembling anchor for bifunctional peptides.23,25,41 Similarly, we 
have previously established the importance of engineering the design of the spacer to 
optimize the function of the antimicrobial peptide domain in the bifunctional peptide 
construct.41 The spacer serves as a link between the two functional domains and is designed 
to preserve the secondary structure of each individual domain, a parameter that is tightly 
linked to antimicrobial function. Here, a novel AMP domain obtained from literature was 
linked to the TiBP through a “spacer5” to create a bifunctional peptide, as previously 
studied.41 The antimicrobial peptide (AMP domain) and the bifunctional peptide was 
selected through a rational design process based on previously determined antimicrobial 
“rules”.23 The minimum inhibitory concentration for the TiBP-spacer5-AMP bifunctional 
peptide was established at 64 iM for an ATCC line of S. mutans (Fig. 1). The bifunctional 
peptide can be evaluated against other oral pathogens which significantly influence the 
initiation and progression of peri-implant disease. Other keystone periodontal pathogens that 
could be evaluated include P. gingivalis, A. actinomycetemcomitans, T. forsythia, T. 
denticola, and P. intermedia.1 As more data are obtained on the function of this peptide 
construct against oral pathogens, the same “rule” induction method could be applied to 
elucidate peptide secondary structure features that are predominant in peptides effective 
against bacteria in addition to S. mutans.23,42
Binding and Rebinding of the Bifunctional Peptide
TiBP-AMP is designed to incorporate a high-affinity titanium implant anchoring peptide 
with an antimicrobial peptide linked through a spacer designed to preserve the function of 
each peptide. The data demonstrate that the selected spacer design preserves not only the 
antimicrobial activity but also the robust anchoring activity to the implant surface through 
the TiBP domain, as seen during repeated retreatment of cleansed bacteria-fouled surfaces as 
would occur for implants already placed in the jaws (Fig. 2, Table I).
TiBP-AMP can be repeatedly applied to a bacte-ria-fouled implant surface to deliver 
antimicrobial properties to address the etiopathogenesis of peri-implant disease. In contrast, 
the Control-AMP (without TiBP) showed minimal absorption to the surface of bacteria-
fouled and cleansed titanium discs (Fig. 2, Table I). This finding of low binding to fouled/
cleaned titanium surfaces indicates that peptide binding is not due simply to nonspecific 
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adherence/absorption to the implant surface, nor to any bacteria debris (biopolymers) 
retained on the fouled surface. The experimental design is based on application of known 
maintenance procedures followed at professional recall appointments39,40 demonstrate that 
the described bifunctional peptide can be successfully reapplied and anchored to the surface 
of a previously fouled and cleaned implant surface.
Antibacterial Functionalization on Implant Discs
Antibacterial and titanium anchoring functions were demonstrated simultaneously on discs 
functionalized with TiBP-AMP when challenged with S. mutans bacteria. The TiBP-AMP 
film successfully demonstrated an antibacterial function with 19.3% dead bacteria, 
compared with 0.2% for the Control- AMP. Additionally, the TiBP-AMP peptide film had 
antibiofouling properties, with 21% total surface coverage by bacteria (living and dead), 
compared with 53.5% (Table II) for the disc treated with the control peptide. Bifunctional 
peptides have previously been used as antibacterial surface agents; however, we demonstrate 
herein their antibacterial and antibiofouling activity following rebinding using a procedure 
that could be performed clinically during professional retreatment appointments. This 
technology represents an advancement in the field over passively absorbed molecules, which 
are subject to leaching and poor performance challenges.23–3 The use of a water delivery 
system for the bifunctional peptide completely eliminates the need for the biologically 
hostile coupling environments typically required for chemically coupling bioactive 
molecules.31–3 The capacity to deliver a water-based bifunctional peptide to implants that 
have been previously placed in the jaw is a paradigm shift, allowing potentially limitless 
retreatment opportunities to control oral biofilms during the life of the implant.
Retreatment Cycle Binding and Reapplication
The novel method applied to reveal peptide anchored on the implant surface is demonstrated 
in Fig. 3. This method ensures specific identification of the bifunctional peptide of interest 
on a titanium surface prepared for integration with bone. This technique also ensures that the 
bifunctional peptide, TiBP-AuBP alone was identified, avoiding noise and not due to 
nonspecific interactions with bacterial biopolymers on the disc surface. The inclusion of the 
AuBP amino acid sequence within green fluorescent protein reveals no discernible effect on 
gold binding.43 The specificity of detection was preserved following up to four cycles of 
fouling/cleansing. The quantitation of the peptides bound to the discs demonstrates that 
precise binding to the titanium surface is preserved. A t test performed on our generated data 
revealed statistical significance based on a (two-tailed) P-value of 0.011. Furthermore, the 
data demonstrate that the amount of peptide bound generally increased slightly with each 
successive fouling cycle, with the exception of cycle 2. The demonstrated preservation of the 
TiBP anchored to the surface strengthens the impact of this technology as a nonsurgical, 
water-based retreatment option for peri-implant disease. Multiple retreatment procedures can 
be performed, extending the lifetime of the implant.
De Novo Secondary Structure Generation
The secondary structures generated demonstrate preservation of the a-helix character of the 
antimicrobial domain, which has previously been linked to antimicrobial function. The 
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engineered spacer is critical to preserving the function of the antimicrobial and binding 
domains.
Titanium Disc Surface Topography
Titanium implant discs were prepared by grit blasting with 180–220 micron titanium dioxide 
particles37,44–46 and sterilization following a widely used protocol similar to that used by 
implant manufacturers to create “active osteoin-tegration” surfaces46 Biocompatibility is an 
essential feature for all implant surfaces, and preserving the surface properties is a 
mandatory design requirement. The average, RMS, and range of the roughness did not 
change significantly after fouling and cleaning for retreatment, or after rebinding of the 
bifunctional peptide film (Fig. 5). These results support the advantage of this approach to 
create not only an antibacterial and antibiofouling implant surface, but also one that is 
competent to support osteointegration and is similar to standards for surface topography 
currently favored by implant manufacturers.
CONCLUSION
A water-based, nonsurgical approach to address peri-implant disease using application of a 
bifunctional peptide film during initial implant placement of new implants or as retreatment 
for existing implants was demonstrated. The functions of the TiBP and AMP domains linked 
by an engineered spacer in a bifunctional peptide were confirmed by identification of the 
minimal inhibitory concentration in solution, as well as by surface antimicrobial activity. 
Moreover, this simple cleansing protocol likely preserved the biocompatibility of the 
titanium implant while reexposing the titanium surface after bacterial fouling to permit 
sufficient rebinding of the bifunctional peptide. The rebound bifunctional TiBP-AMP 
peptide film exhibited antibacterial and antibiofouling activity over four fouling/cleaning 
cycles. The modularity of this approach enables it to be combined with our next generation 
peptide engineering methodologies to improve both the titanium binding and antimicrobial 
properties of the peptide film, which could lead to better coverage, with higher rebinding 
affinity and antimicrobial effectiveness, respectively. This technology represents a paradigm 
shift in prevention of dental implant failure while adding to the range of bioactive molecules 
that can be anchored to implant surfaces to improve their function, such as osteointegration.
47
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
Discussions with colleagues were instructive and appreciated. The comments of the anonymous reviewer improved 
the manuscript.
FUNDING
Supported by R21 AR062249 (CT) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 
and R43 DE027306 (MLS/YZ) from the National Institute for Dental and Craniofacial Research (NIDCR) of the 
National Institutes of Health, Bethesda, MD, 20892.
WISDOM et al. Page 10














1. Listgarten MA, Periodontology 2000, 5 (1994).
2. Tarnow DP, J. Dent. Res. 95, 1 (2016). 10.1177/0022034515616557.
3. Valente NA and Andreana S, J. Periodontal. Implant. Sci. 46, 3 (2016). 10.5051/jpis.2016.46.3.136.
4. Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, 
Derks J, Figuero E, Hammerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert 
F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, and 
Zitzmann N, J. Periodontol. 89, S313 (2018). 10.1002/jper.17-0739. [PubMed: 29926955] 
5. Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, Mealey BL, Papapanou 
PN, Sanz M, and Tonetti MS, J. Periodontol. 89, S1 (2018). 10.1002/jper.18-0157. [PubMed: 
29926946] 
6. Salvi GE, Cosgarea R, and Sculean A, J. Dent. Res. 96, 1 (2017). 10.1177/0022034516667484.
7. Achermann G, How will dentistry look in 2020?, Vision 2020: Simply doing more for dental 
professionals (2012), http://www.straumann.com.
8. Karoussis IK, Kotsovilis S, and Fourmousis I, Clin. Oral Implants Res. 18, 6 (2007). https://doi.org/
10.1111Zj.1600-0501.2007.01406.x.
9. Kotsovilis S, Karoussis IK, and Fourmousis I, Clin. Oral Implants Res. 17, 5 (2006). 10.1111/j.
1600-0501.2005.01245.x.
10. Muddugangadhar BC, Amarnath GS, Sonika R, Chheda PS, and Garg A, J. Int. Oral Health 7, 9 
(2015).
11. Moraschini V, Poubel LA, Ferreira VF, and Barboza Edos S., Int. J. Oral Maxillofac. Surg. 44, 3 
(2015). 10.1016/j.ijom.2014.10.023.
12. Derks J, Hakansson J, Wennstrom JL, Tomasi C, Larsson M, and Berglundh T, J. Dent. Res. 94, 44 
(2015). 10.1177/0022034514563077. [PubMed: 25355774] 
13. Bryant SR and Zarb GA, J. Can. Dent. Assoc. 68, 2 (2002).
14. Koldsland OC, Scheie AA, and Aass AM, J. Periodontol. 81, 2 (2010). 10.1902/jop.2009.090269.
15. Greenstein G, Cavallaro J Jr, and Tarnow D, Dent. Clin. North Am. 54, 1 (2010). 10.1016/j.cden.
2009.08.008. [PubMed: 20103469] 
16. Esposito M, Grusovin MG, Tzanetea E, Piattelli A, and Worthington HV, Cochrane Database Syst. 
Rev., 6(2010) 10.1002/14651858.cd004970.pub4.
17. Esposito M, Ardebili Y, and Worthington HV, Cochrane Database Syst. Rev., 7(2014) 
10.1002/14651858.cd003815.pub4.
18. Derks J, Schaller D, Hakansson J, Wennstrom JL, Tomasi C, and Berglundh T, J. Dent. Res. 95, 1 
(2016). 10.1177/0022034515608832.
19. Lang NP, Wilson TG, and Corbet EF, Clin. Oral Implants Res., 11 Suppl 1(2000).
20. Esposito M, Grusovin MG, and Worthington HV, Cochrane Database Syst. Rev., 1(2012) 
10.1002/14651858.cd004970.pub5.
21. Grusovin MG, Coulthard P, Worthington HV, George P, and Esposito M, Cochrane Database Syst. 
Rev., 8(2010) 10.1002/14651858.cd003069.pub4.
22. Louropoulou A, Slot DE, and Van der Weijden F, Clin. Oral Implants Res. 26, 7 (2015). 10.1111/
clr.12365.
23. Yucesoy DT, Hnilova M, Boone K, Arnold PM, Snead ML, and Tamerler C, JOM 67, 4 (2015). 
10.1007/s11837-015-1350-7.
24. Gitelman A and Rapaport H, Langmuir 30, 16 (2014). 10.1021/la500310n.
25. Yazici H, Fong H, Wilson B, Oren EE, Amos FA, Zhang H, Evans JS, Snead ML, Sarikaya M, and 
Tamerler C, Acta Biomater. 9, 2 (2013). 10.1016/j.actbio.2012.11.004.
26. Vidal G, Blanchi T, Mieszawska AJ, Calabrese R, Rossi C, Vigneron P, Duval JL, Kaplan DL, and 
Egles C, Acta Biomater. 9, 1 (2013). https://doi.org/10.1016Zj.actbio.2012.09.003.
27. Beyeler M, Schild C, Lutz R, Chiquet M, and Trueb B, Exp. Cell Res. 316, 7 (2010). 10.1016/
j.yexcr.2009.12.019.
WISDOM et al. Page 11













28. Reyes CD, Petrie TA, Burns KL, Schwartz Z, and Garcia AJ, Biomaterials 28, 21 (2007). 10.1016/
j.biomaterials.2007.04.003.
29. Auernheimer J, Zukowski D, Dahmen C, Kantlehner M, Enderle A, Goodman SL, and Kessler H, 
ChemBioChem 6, 11 (2005). 10.1002/cbic.200500031.
30. Schliephake H, Scharnweber D, Dard M, Rossler S, Sewing A, Meyer J, and Hoogestraat D, Clin. 
Oral Implants Res. 13, 3 (2002). 10.1034/j.1600-0501.2002.130312.x.
31. Castner DG and Ratner BD, Surf. Sci. 500, 1–3 (2002). 10.1016/s0039-6028(01)01587-4.
32. Tomsia AP, Launey ME, Lee JS, Mankani MH, Wegst UGK, and Saiz E, Int J. Oral. Maxillofac. 
Implants, 26(2011).
33. Cranford SW, de Boer J, van Blitterswijk C, and Buehler MJ, Adv. Mater. 25, 6 (2013). 10.1002/
adma.201202553.
34. Maia FR, Bidarra SJ, Granja PL, and Barrias CC, Acta Biomater. 9, 11 (2013). 10.1016/j.actbio.
2013.08.004.
35. Koidou VP, Argyris PP, Skoe EP, Mota Siqueira J., Chen X, Zhang L, Hinrichs JE, Costalonga M, 
and Aparicio C, Biomater. Sci, 6, 7(2018) 10.1039/c8bm00300a.
36. Wohlfahrt JC, Evensen BJ, Zeza B, Jansson H, Pilloni A, Roos-Jansaker AM, Di Tanna GL, Aass 
AM, Klepp M, and Koldsland OC, Int. J. Implant Dent. 3, 1 (2017). 10.1186/s40729-017-0098-y. 
[PubMed: 28101784] 
37. Ronold HJ, Lyngstadaas SP, and Ellingsen JE, Biomaterials 24, 25 (2003).
38. ATCC, ATCC Bacterial Culture Guide, https://www.atcc.org/~/media/PDFs/Culture%20Guides/
ATCC_Bacterial_Culture_Guide.ashx.
39. Bizzarro S, Van der Velden U, and Loos BG, J. Clin. Periodontol. 43, 9 (2016). 10.1111/jcpe.
12578.
40. Jurczyk K, Nietzsche S, Ender C, Sculean A, and Eick S, Clin. Oral Investig. 20, 8 (2016). 
10.1007/s00784-016-1711-9.
41. Wisdom C, VanOosten SK, Boone KW, Khvostenko D, Arnold PM, Snead ML, and Tamerler C, J. 
Mol. Eng. Mater. 4, 01 (2016).
42. Boone K, Camarda K, Spencer P, and Tamerler C, BMC Bioinformatics, 19(2018). 10.1186/
s12859-018-2514-6.
43. Yuca E and Tamerler C, JOM (in press). 10.1007/s11837-018-03325-3.
44. Ronold HJ, Lyngstadaas SP, and Ellingsen JE, J. Biomed. Mater. Res. A 67, 2 (2003). 10.1002/
jbm.a.10580.
45. Ronold HJ, Ellingsen JE, and Lyngstadaas SP, J. Mater. Sci. Mater. Med. 14, 10 (2003).
46. Monjo M, Ramis JM, Ronold HJ, Taxt-Lamolle SF, Ellingsen JE, and Lyngstadaas SP, Clin. Oral 
Implants Res. 24, 9 (2013). 10.1111/j.1600-0501.2012.02496.x.
47. Zhou Y, Snead ML and Tamerler C, Nanomedicine. 11, 2 (2015). 10.1016/j.nano.2014.10.003.
WISDOM et al. Page 12














Concentration of TiBP-AMP peptide in solution required to inhibit bacterial growth of 
Streptococcus mutans. Growth was measured every 30 min for 24 h by absorbance at 600 
nm and plotted as growth curves representing the increase of bacteria over time. The 
inhibitory concentration for TiBP-AMP was determined to be 64 μM.
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Fluorescence microscopy images of bifunctional peptide binding and antimicrobial activity 
on titanium implant discs. Binding and rebinding with 100 μM of either bifunctional peptide 
was identified with a fluorescent dye. In the larger 3D images, the z-axis height corresponds 
to fluorescence intensity, while the smaller insert images correspond to 2D representations. 
Rebinding was performed on a once-fouled S.mutans implant disc. The antibacterial 
properties of the bifunctional peptides against S.mutans are shown using a Live/Dead (L/D) 
assay to differentiate live (green) from dead (red) bacteria present on the disc surface. Scale 
bar = 100 μm.
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Fluorescence microscopy images of binding/rebinding on implant discs fouled multiple 
times by bacteria. A bifunctional peptide composed of the titanium binding peptide (TiBP) 
and a gold binding peptide (AuBP) was bound to the titanium disc and to gold nanoparticles 
(AuNP). A fusion protein, green fluorescent protein (GFPuv), fused to AuBP was 
subsequently bound to the AuNP immobilized on the titanium surface by the TiBP-AuBP 
bifunctional peptide. Schematics at the top of the figure represent the layer-by-layer 
assembly procedure used for imaging. After each addition, the surfaces were washed to 
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remove any non-specifically bound peptides. Fluorescence images were obtained at each 
step and are shown. The procedure was repeated for multiple rounds of fouling to model 
multiple retreatment visits for implant surfaces affected by peri-implant disease. Scale bar = 
200 μm.
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De novo secondary structures of the bifunctional peptides studied. The structures have been 
recolored according to the domains in each bifunctional peptide. In all structures, the 
titanium binding peptide is blue, the spacer peptide is black, and the antimicrobial peptide 
domain is red.
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Surface topography characterization by optical profilometry. Optical profilometry images 
were collected and analyzed for sterile discs (Sterile), discs following bacterial fouling and 
the clinical cleaning procedure (Post Clean), and TiBP-AMP rebound to the fouled and 
cleaned disc surface. The lack of statistical difference (n = 5) for the average, RMS, and 
range of the roughness indicates that the surface topography prepared as an optimized 
surface for osteointegration was preserved through cleaning and rebinding
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Table I.
Quantitative results for the binding and rebinding of the bifunctional peptides shown in Fig. 2
TiBP-AMP (%) Control-AMP (%)
Bind 46.8 0.2
Rebind 28.5 0.2
Results represent the percentage surface coverage of the peptide measured by ImageJ software analysis. Approximately 60% of the initial binding 
to a sterile implant disc was preserved on rebinding to a one-time S. mutans-fouled implant disc.
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Table II.
Quantitative results from the live/dead images of S. mutans bacteria on implant discs treated with bifunctional 
peptides shown in Fig. 2
TiBP-AMP (%) Control-AMP (%)
Live   1.7 53.3
Dead 19.3   0.2
Total coverage 21.0 53.5
Results represent the percentage surface coverage of live and dead bacteria measured by ImageJ software analysis. TiBP-AMP resulted in a more 
effective antibacterial and anti-biofouling surface, represented by a higher percentage coverage of dead bacteria and lower total percentage of 
bacterial coverage on the surface.
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Table III.
Fluorescence microscopy image quantification by measuring the percentage surface coverage of the images 
using ImageJ software
Treatment cycle Surface coverage (%)
Sterile 18.3
1 × foul 24.3
2 × foul   8.6
3 × foul 32.9
4 × foul 41.5
The percent surface coverage of the TiBP-AuBP + AuNP + GFPuv-AuBP assembly on titanium discs is depicted for sterile new discs and for discs 
fouled and then cleaned for up to four retreatment cycles.
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